Black Diamond Stock Outlook After Q1 Beat and Cash Runway

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
MarketBeat on MSN

Black Diamond Therapeutics lung cancer drug shows 15.2-month PFS in phase 2 study

Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell ...

What's going on with Black Diamond Therapeutics stock Tuesday?

Black Diamond Therapeutics, Inc. BDTX stock climbed in Tuesday's session. The company recently reported encouraging Phase 2 ...

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in ...

Black Diamond Therapeutics, Inc.

View Black Diamond Therapeutics, Inc. BDTX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...
Forbes

Black Diamond Pursuit FLZ Trekking Poles Review: Travel-Ready Poles Designed For Most Adventures

I’m the proud owner of too much hiking gear. I’ve got different shoes for different occasions, layers upon layers of moisture-wicking clothing and plenty of weather-specific accessories like gaiters ...